personalized medicine
The firm is offering molecular diagnostic testing and clinical trial services to bridge knowledge gaps and increase access to personalized care locally.
Cancer Research UK, Guardant Health Ink Research, Data Sharing Partnership
The collaboration aims to help accelerate the discovery and development of cancer drugs and diagnostics through ongoing and potentially new clinical trials.
Investigators highlighted data from efforts in breast and bladder cancer, demonstrating that the company's platform could help oncologists better personalize treatment.
Burning Rock, Boehringer Ingelheim Ink Master Service Agreement for Oncology Companion Diagnostics
The companies will focus initially on Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin, now being studied in a new Phase II trial in China.
Genomic Profiling Aids Patients With Cancers of Unknown Primary in Trial, Though Benefit is Limited
In the CUPISCO trial, molecularly guided treatment reduced the risk of progression or death by 28 percent compared to patients receiving chemotherapy.